Related Experiment Videos
[10 years experience with extracorporeal membrane oxygenation]
1Anaesthesiologische Universitätsklinik Freiburg. mols@ana1.ukl.uni-freiburg.de
Summary
Extracorporeal membrane oxygenation (ECMO) may improve survival in severe acute respiratory distress syndrome (ARDS) patients. This study found similar survival rates between ECMO and non-ECMO groups, with few complications.
Area of Science:
- Critical Care Medicine
- Respiratory Medicine
- Cardiopulmonary Support
Background:
- Severe acute respiratory distress syndrome (ARDS) necessitates advanced supportive therapies.
- Extracorporeal membrane oxygenation (ECMO) is utilized for refractory ARDS.
- Limited data exists on ECMO outcomes in ARDS cohorts.
Purpose of the Study:
- To evaluate the outcomes, clinical parameters, and complications of ARDS patients treated with ECMO.
- To compare survival rates between ECMO and conventional therapy in ARDS.
- To identify predictors of prognosis in ECMO-treated ARDS patients.
Main Methods:
- Prospective data collection of 245 ARDS patients from 1991-1999.
- Comparison of outcomes between 62 ECMO patients and 183 non-ECMO patients.
- Analysis of clinical parameters and complications.
Main Results:
- Overall survival was 55% in the ECMO group and 61% in the non-ECMO group.
- ECMO treatment was associated with a low incidence of complications, including one fatal event.
- No pre-treatment or during-treatment parameters reliably predicted individual prognosis.
Conclusions:
- ECMO is a viable therapeutic option for selected severe ARDS patients.
- While ECMO may increase survival, a definitive randomized controlled trial is still needed.
- ECMO should be considered in severe ARDS cases pending superior therapies.